Tissue Regenix Group plc (LON:TRX – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 62.02 ($0.78) and traded as low as GBX 60 ($0.76). Tissue Regenix Group shares last traded at GBX 61 ($0.77), with a volume of 37,110 shares.
Tissue Regenix Group Stock Down 0.8 %
The firm has a market cap of £43.45 million, a price-to-earnings ratio of -6,100.00 and a beta of 1.61. The stock has a 50-day moving average of GBX 57.41 and a 200-day moving average of GBX 62.02. The company has a current ratio of 3.74, a quick ratio of 2.36 and a debt-to-equity ratio of 35.69.
About Tissue Regenix Group
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.
See Also
- Five stocks we like better than Tissue Regenix Group
- High Flyers: 3 Natural Gas Stocks for March 2022
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Most Volatile Stocks, What Investors Need to Know
- Top-Performing Non-Leveraged ETFs This Year
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.
